AHA report demonstrates benefits of 340B program
The AHA May 25 published a report on the 340B Drug Pricing Program, its history and value to hospitals and patients, and details on 340B contract pharmacy arrangements.
“The 340B program plays an important public policy role in ensuring access to essential drugs and services for low-income and underserved Americans receiving care at 340B hospitals nationwide,” the report concludes. “Without the program, many patients could have trouble accessing affordable medications and critical health services, jeopardizing their health and well-being.”
Related News Articles
Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program. “When…
Blog
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…